ArticleThe American journal of tropical medicine and hygiene2015
Seroreactivity to a large panel of field-derived Plasmodium falciparum apical membrane antigen 1 and merozoite surface protein 1 variants reflects seasonal and lifetime acquired responses to malaria.
Abstract read
In one paragraph
Article in The American journal of tropical medicine and hygiene, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- RTS,S vaccination is associated with serologic evidence of decreased exposure to Plasmodium falciparum liver- and blood-stage parasites.Molecular & cellular proteomics : MCP · 2015Trial
- Controlled human malaria infection with NF54 and 7G8 strains elicit differential antibody responses to Plasmodium falciparum peptides.Frontiers in immunology · 2025Article
- Children with hemoglobin C or S trait have low serologic responses to a subset of malaria variant surface antigens.The Journal of infection · 2024Article
- Characterization of a novelFrontiers in immunology · 2023Article
- Protein Microarrays as a Tool to Analyze Antibody Responses to Variant Surface Antigens Expressed on the Surface of Plasmodium falciparum-Infected Erythrocytes.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Malian adults maintain serologic responses to virulent PfEMP1s amid seasonal patterns of fluctuation.Scientific reports · 2021Article
- Comparison of ELISA with electro-chemiluminescence technology for the qualitative and quantitative assessment of serological responses to vaccination.Malaria journal · 2020Article
- Microarray analyses reveal strain-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 variants following natural infection and vaccination.Scientific reports · 2020Article
- Serologic responses to the PfEMP1 DBL-CIDR head structure may be a better indicator of malaria exposure than those to the DBL-α tag.Malaria journal · 2019Article
- Antibodies to Peptides in Semiconserved Domains of RIFINs and STEVORs Correlate with Malaria Exposure.mSphere · 2019Article
- Convalescent Plasmodium falciparum-specific seroreactivity does not correlate with paediatric malaria severity or Plasmodium antigen exposure.Malaria journal · 2018Article
- Children with cerebral malaria or severe malarial anaemia lack immunity to distinct variant surface antigen subsets.Scientific reports · 2018Article
- A deep sequencing approach to estimate Plasmodium falciparum complexity of infection (COI) and explore apical membrane antigen 1 diversity.Malaria journal · 2017Article
- Review
- Biosignatures of Exposure/Transmission and Immunity.The American journal of tropical medicine and hygiene · 2015Article
- Novel serologic biomarkers provide accurate estimates of recent Plasmodium falciparum exposure for individuals and communities.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Differential recognition of terminal extracellular Plasmodium falciparum VAR2CSA domains by sera from multigravid, malaria-exposed Malian women.The American journal of tropical medicine and hygiene · 2015Article
- Expanding the toolbox in pursuit of a strain transcendent malaria vaccine.The American journal of tropical medicine and hygiene · 2015Article
Corrections and comments
- Commented on by
Authors and funding
18 authors.
Jason A BaileyHoward Hughes Medical Institute/Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland; Division of Infectious Diseases, Department of Medicine, University of California, Irvine, California; Laboratory of Immunogenetics, National Institutes of Health, Bethesda, Maryland; Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, University of Sciences, Techniques and Technology, Bamako, Mali.
Jozelyn PabloHoward Hughes Medical Institute/Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland; Division of Infectious Diseases, Department of Medicine, University of California, Irvine, California; Laboratory of Immunogenetics, National Institutes of Health, Bethesda, Maryland; Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, University of Sciences, Techniques and Technology, Bamako, Mali.
Amadou NiangalyHoward Hughes Medical Institute/Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland; Division of Infectious Diseases, Department of Medicine, University of California, Irvine, California; Laboratory of Immunogenetics, National Institutes of Health, Bethesda, Maryland; Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, University of Sciences, Techniques and Technology, Bamako, Mali.
Mark A TravassosHoward Hughes Medical Institute/Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland; Division of Infectious Diseases, Department of Medicine, University of California, Irvine, California; Laboratory of Immunogenetics, National Institutes of Health, Bethesda, Maryland; Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, University of Sciences, Techniques and Technology, Bamako, Mali.
Amed OuattaraHoward Hughes Medical Institute/Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland; Division of Infectious Diseases, Department of Medicine, University of California, Irvine, California; Laboratory of Immunogenetics, National Institutes of Health, Bethesda, Maryland; Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, University of Sciences, Techniques and Technology, Bamako, Mali.
Drissa CoulibalyHoward Hughes Medical Institute/Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland; Division of Infectious Diseases, Department of Medicine, University of California, Irvine, California; Laboratory of Immunogenetics, National Institutes of Health, Bethesda, Maryland; Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, University of Sciences, Techniques and Technology, Bamako, Mali.
Matthew B LaurensHoward Hughes Medical Institute/Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland; Division of Infectious Diseases, Department of Medicine, University of California, Irvine, California; Laboratory of Immunogenetics, National Institutes of Health, Bethesda, Maryland; Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, University of Sciences, Techniques and Technology, Bamako, Mali.
Shannon L Takala-HarrisonHoward Hughes Medical Institute/Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland; Division of Infectious Diseases, Department of Medicine, University of California, Irvine, California; Laboratory of Immunogenetics, National Institutes of Health, Bethesda, Maryland; Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, University of Sciences, Techniques and Technology, Bamako, Mali.
Kirsten E LykeHoward Hughes Medical Institute/Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland; Division of Infectious Diseases, Department of Medicine, University of California, Irvine, California; Laboratory of Immunogenetics, National Institutes of Health, Bethesda, Maryland; Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, University of Sciences, Techniques and Technology, Bamako, Mali.
Jeff SkinnerHoward Hughes Medical Institute/Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland; Division of Infectious Diseases, Department of Medicine, University of California, Irvine, California; Laboratory of Immunogenetics, National Institutes of Health, Bethesda, Maryland; Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, University of Sciences, Techniques and Technology, Bamako, Mali.
Andrea A BerryHoward Hughes Medical Institute/Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland; Division of Infectious Diseases, Department of Medicine, University of California, Irvine, California; Laboratory of Immunogenetics, National Institutes of Health, Bethesda, Maryland; Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, University of Sciences, Techniques and Technology, Bamako, Mali.
Algis JasinskasHoward Hughes Medical Institute/Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland; Division of Infectious Diseases, Department of Medicine, University of California, Irvine, California; Laboratory of Immunogenetics, National Institutes of Health, Bethesda, Maryland; Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, University of Sciences, Techniques and Technology, Bamako, Mali.
Rie Nakajima-SasakiHoward Hughes Medical Institute/Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland; Division of Infectious Diseases, Department of Medicine, University of California, Irvine, California; Laboratory of Immunogenetics, National Institutes of Health, Bethesda, Maryland; Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, University of Sciences, Techniques and Technology, Bamako, Mali.
Bourema KouribaHoward Hughes Medical Institute/Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland; Division of Infectious Diseases, Department of Medicine, University of California, Irvine, California; Laboratory of Immunogenetics, National Institutes of Health, Bethesda, Maryland; Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, University of Sciences, Techniques and Technology, Bamako, Mali.
Mahamadou A TheraHoward Hughes Medical Institute/Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland; Division of Infectious Diseases, Department of Medicine, University of California, Irvine, California; Laboratory of Immunogenetics, National Institutes of Health, Bethesda, Maryland; Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, University of Sciences, Techniques and Technology, Bamako, Mali.
Philip L FelgnerHoward Hughes Medical Institute/Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland; Division of Infectious Diseases, Department of Medicine, University of California, Irvine, California; Laboratory of Immunogenetics, National Institutes of Health, Bethesda, Maryland; Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, University of Sciences, Techniques and Technology, Bamako, Mali.
Ogobara K DoumboHoward Hughes Medical Institute/Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland; Division of Infectious Diseases, Department of Medicine, University of California, Irvine, California; Laboratory of Immunogenetics, National Institutes of Health, Bethesda, Maryland; Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, University of Sciences, Techniques and Technology, Bamako, Mali.
Christopher V PloweHoward Hughes Medical Institute/Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland; Division of Infectious Diseases, Department of Medicine, University of California, Irvine, California; Laboratory of Immunogenetics, National Institutes of Health, Bethesda, Maryland; Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, University of Sciences, Techniques and Technology, Bamako, Mali cplowe@medicine.umaryland.edu.
Funding
EXPAND PARTICIPATION BY MINORITIES IN BIOMEDICAL SCIENCER25GM055036 · NIGMS · UNIVERSITY OF MARYLAND BALTIMORE COUNTY · PI SUMMERS, MICHAEL FINLEY · 1996 to 2021
$16.9MMALARIA RESEARCH TRAINING IN MALID43TW001589 · FIC · UNIVERSITY OF MARYLAND BALTIMORE · PI PLOWE, CHRISTOPHER V. · 2000 to 2015
$2.8MImmuno-epidemiological epitope mapping of a blood stage malaria vaccine antigenR01AI093635 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI PLOWE, CHRISTOPHER V. · 2012 to 2015
$2.3MPredicting naturally acquired humoral immunity against malariaR01AI095916 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI FELGNER, PHILIP LOUIS · 2012 to 2016
$2.1MFIC NIH HHS D43 TW001589NIAID NIH HHS R01 AI093635NIAID NIH HHS R01 AI095916NIGMS NIH HHS R25 GM055036
Abstract
Parasite antigen diversity poses an obstacle to developing an effective malaria vaccine. A protein microarray containing Plasmodium falciparum apical membrane antigen 1 (AMA1, n = 57) and merozoite surface protein 1 19-kD (MSP119, n = 10) variants prevalent at a malaria vaccine testing site in Bandiagara, Mali, was used to assess changes in seroreactivity caused by seasonal and lifetime exposure to malaria. Malian adults had significantly higher magnitude and breadth of seroreactivity to variants of both antigens than did Malian children. Seroreactivity increased over the course of the malaria season in children and adults, but the difference was more dramatic in children. These results help to validate diversity-covering protein microarrays as a promising tool for measuring the breadth of antibody responses to highly variant proteins, and demonstrate the potential of this new tool to help guide the development of malaria vaccines with strain-transcending efficacy.
Indexed as
SeasonsAdultAnimalsAntigens, ProtozoanChildHumansMalaria, FalciparumMembrane ProteinsMerozoite Surface Protein 1Plasmodium falciparumProtozoan ProteinsAntigens, Protozoanapical membrane antigen I, PlasmodiumMembrane ProteinsMerozoite Surface Protein 1Protozoan Proteins
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.